Vikas Ostwal

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 196 citations · Full text

Overall Survival, Gastrointestinal Oncology, Medicine +7

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Jørn Herrstedt, Rebecca Clark-Snow, Christina H. Ruhlmann et al. · ESMO Open · 2024 · 114 citations · Full text

Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC)

L. Bengt van Rijssen, Arja Gerritsen, Inge Henselmans et al. · Annals of Surgery · 2017 · 59 citations · Full text

Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease

Rahul V. Parghane, Vikas Ostwal, Anant Ramaswamy et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 44 citations

Surgical Oncology, “ Sandwich, Novel Treatment Strategy +8

A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study)

Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava et al. · Medical Oncology · 2022 · 29 citations

Pro-oxidant Combination, Oncology, Chemoprevention Strategy +9